All In MedTech

Device Trial Radar · NCT04421378

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

74

Actual

Start

Jun 8, 2020

Primary completion

Jul 3, 2023

Study completion Jul 3, 2023

Sponsor

Lead sponsor
Karyopharm Therapeutics IncNot on our public-company list
Sponsor type
Industry
First posted
Jun 9, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C). * Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT * Arm B: evaluating the combination of selinexor with radiation therapy and temozolomide (TMZ) (S-TRT) in nGBM participants with methylated-O6-methylguanine-DNA-methyltransferase (mMGMT) * Arm C: evaluating the combination of selinexor with lomustine (or carmustine, if lomustine is not available) (S-L/C) in rGBM participants regardless of MGMT status * Arm D: evaluating the combination of selinexor with bevacizumab in rGBM participants regardless of MGMT status * Arm E: evaluating the combination of selinexor with tumor treating fields (TTField) in rGBM participants regardless of MGMT status

Conditions

  • Glioblastoma Multiforme

Interventions

  • SelinexorDrug

    Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

  • Temozolomide (TMZ)Drug

    Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral

  • Lomustine (CCNU)Drug

    Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral

  • Standard Fractionated Radiation therapy (RT)Radiation

    Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

  • BevacizumabDrug

    Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous

  • TTFieldDevice

    Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.

  • CarmustineDrug

    Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a and 1b: Maximum Tolerated Dose of SelinexorTime frame: At Cycle 1 (up to 42 days)
  2. Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of SelinexorTime frame: From Cycle 1 Day 1 up to 14 days after last dose (up to 15.41 months) (Each Cycle length = up to 42 days)
  3. Phase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEsTime frame: From first dose of study treatment up to 30 days post last dose (Up to 16.41 months)

2 more outcomes with a free account

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center)

    Los Angeles, California

  • University of California

    San Francisco, California

15 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.